

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Characterization of heterologously expressed fibril filaments, a shape and motility determining cytoskeletal protein of the helical bacterium *Spiroplasma*

Shrikant Harne ^a and Pananghat Gayathri ^{a #}

^a Indian Institute of Science Education and Research (IISER) Pune,

Dr. Homi Bhabha Road, Pashan, Pune, India

Author for correspondence

E mail ID: gayathri@iiserpune.ac.in

1

2 **Abstract (200 words)**

3 Fibril is a constitutive filament forming cytoskeletal protein of unidentified fold, exclusive
4 to members of genus *Spiroplasma*. It is hypothesized to undergo conformational
5 changes necessary to bring about *Spiroplasma* motility through changes in body
6 helicity. However, in the absence of a cofactor such as nucleotide that binds to the
7 protein and drives polymerization, the mechanism driving conformational changes in
8 fibril remains unknown. Sodium dodecyl sulphate (SDS) solubilized the fibril filaments
9 and facilitated fibril purification by affinity chromatography. An alternate protocol for
10 obtaining enriched insoluble fibril filaments has been standardized using density
11 gradient centrifugation method. Visualization of purified protein using electron
12 microscopy demonstrated that it forms filament bundles. Probable domain boundaries of
13 fibril protein were identified based on mass spectrometric analysis of proteolytic
14 fragments. Presence of both α -helical and β -sheet signatures in FT-IR measurements
15 suggests that fibril filaments consist of assembly of folded globular domains, and not a
16 β -strand based aggregation similar to amyloid fibrils.

17

18 **Key words:** *Spiroplasma* fibril, sodium dodecyl sulphate, electron microscopy, bacterial
19 cytoskeleton

20

1 Introduction

2 Fibril is a *Spiroplasma*-specific nucleotide-independent filament forming protein^{1,2}. It is
3 a homo-polymer of a 59,000 Da protein called fib or fibril that is proposed to be
4 organized as a polymeric assembly³. It is a bi-domained protein, consisting of an N-
5 terminal domain approximately 30 % similar to 5'-methylthioadenosine nucleosidase
6 (MTAN) and a C-terminal domain of unidentified fold^{4,5}. A set of fibril polymers and
7 MreB filaments are present on the cytoplasmic side of the cell membrane and
8 constitutes the cytoskeletal ribbon (Figure 1A)^{6,7}. The ribbon has been proposed to
9 confer helical shape and to function as a linear motor contributing to motility of
10 spiroplasmas^{3,6-10}. However, the detailed molecular architecture of fibril and the
11 cytoskeletal ribbon remains to be determined.

12 According to the current model for *Spiroplasma* motility, fibril undergoes conformational
13 changes to bring about length variations in the fibril filaments^{3,4,8}. Co-ordinated cycles
14 of alternate contraction and extension of the fibril filaments can cause change in
15 handedness of the cell body that are reflected in the form of kinks which push the
16 surrounding liquid and propel the cell forward^{3,6,9}. Indeed, low resolution electron
17 microscopy data suggests the possibility of different conformations of fibril^{4,11}. The
18 molecular mechanism of kink propagation based on conformational changes of a
19 constitutive filament such as fibril is also unknown.

20 Apart from fibril, MreB is a constituent of the cytoskeletal ribbon of *Spiroplasma*⁶. The
21 role of MreB in *Spiroplasma* motility was speculated long ago^{12,13} but was
22 experimentally demonstrated recently¹⁰. Although MreB5 (one of the 5 MreB homologs

1 in *Spiroplasma*) binds fibril and membrane ¹⁰, it is currently not known if MreB links fibril
2 to the membrane. The fact that MreB3 and MreB5 form ATP-dependent dynamic
3 polymers *in vitro* ^{14,15} suggests their possible role as the motor which induces changes
4 in the cytoskeletal ribbon *in vivo*. However, the organization of the cytoskeletal ribbon,
5 consisting of MreBs and fibril filaments, inside *Spiroplasma* cell is under debate (Figure
6 1A) ^{6,7,16}.

7 Recent advances in electron cryomicroscopy allow us to obtain three-dimensional
8 reconstruction of proteins and their assemblies at atomic resolution ^{17,18}. A high
9 resolution structure of fibril may facilitate identification of conformational changes ⁸
10 proposed to be necessary for bringing about kinking motility of *Spiroplasma* ^{5,9}. The
11 structure may also provide insights about the evolution of fibril and the uncharacterized
12 mode of motility driven by cytoskeletal filaments.

13 Here, we demonstrate that fibril expressed in *E. coli* forms filamentous assemblies
14 which are very stable and can withstand SDS treatment. Solubilization of the filaments
15 using SDS enabled purification of fibril polymers formed by a hexahistidine-tagged
16 construct using affinity chromatography. Alternatively, fibril was also purified using
17 density gradient centrifugation without the use of SDS. Visualization of fibril obtained by
18 these protocols using electron microscope showed polymers similar to those reported
19 from *Spiroplasma* cells ⁵. Fibril filaments and their secondary structure content remained
20 unaffected by SDS treatment, based on observation using electron microscopy and FT-
21 IR (Fourier Transform Infrared) spectra. Mass spectrometric characterization of
22 proteolytic fragments confirmed a probable domain boundary for the folded fibril
23 monomers.

1 The study paves the way for further characterization of fibril function using biochemical
2 assays for studying binding of fibril with other bacterial cytoskeletal proteins such as
3 MreBs, to probably unravel a mechanism based on filament interactions between
4 multiple cytoskeletal proteins. Further, the heterologous expression enables us to
5 generate suitable mutant constructs for understanding the enigma behind *Spiroplasma*
6 motility, which was hitherto hindered because of challenges in genetic manipulation of
7 *Spiroplasma*. The variety of approaches used for obtaining structural insights on fibril
8 provides a workflow of options for characterization of challenging assemblies of
9 cytoskeletal filaments.

10 **Material and methods**

11 **Cloning**

12 The *fibril* gene was amplified from genomic DNA of *S. melliferum* (DSMZ accession
13 number 21833) using appropriate primers (Supplementary table S1). Six TGA codons
14 (corresponding to amino acid number 26, 200, 258, 316, 323 and 342 from amino
15 terminus) in *fibril* gene were mutated to TGG and full-length *fibril* gene with modified
16 tryptophan codons was cloned into pHIS17 vector (Addgene plasmid #78201) with or
17 without a terminal hexa-histidine (His₆) tag either at the N-terminus or at the C-terminus.
18 All the clones were confirmed by sequencing (Supplementary table S1).

19 **Expression**

20 The full-length *fibril* gene with modified tryptophan codons was used for expression of
21 fibril protein with or without a terminal (His₆) tag in *E. coli* cells. All the fibril constructs
22 were overexpressed in *E. coli* BL21 (AI) cells (Invitrogen) by growing the transformants

1 in Luria Bertani (LB) broth supplemented with ampicillin (100 µg/mL final concentration)
2 at 37 °C under shaking conditions until OD₆₀₀ reached 0.6. The cultures were then
3 induced with sterile L-arabinose (final concentration 0.2 %) and were grown post-
4 induction at 25 °C for 6 hours. Protein overexpression was confirmed by the presence of
5 high intensity band with molecular weight of ~ 59,000 Da on the SDS-PAGE gel.

6 **Solubility check of fibril**

7 During initial attempts to purify fibril the clarified lysate was spun at 159,000 xg to
8 separate filamentous proteins from monomeric or oligomeric components. Accordingly,
9 fibril was obtained in the pellet fraction. However, fibril from the pellet could not be
10 solubilized and hence required screening of different compounds for their ability to
11 solubilize fibril.

12 **Standardization for solubility of fibril protein**

13 Pellet obtained from 1.2 L culture expressing His₆-fibril was re-suspended in 270 mL of
14 lysis buffer base [10 mM Tris (pH 7.6), 1 % (v/v) Triton-X 100 and 2 M glycerol]. Cells
15 were lysed and the lysate was equally divided into 6 tubes. Multiple solubilization
16 conditions for the lysate were tested with one of the following detergents added to buffer
17 base: N-lauroyl sarcosine sodium salt (LSS; 0.5 % w/v), Sodium deoxycholate (1 %
18 w/v), Tween-20 (1 % v/v), sodium dodecyl sulphate (SDS; 1 % w/v), EDTA (20 mM w/v).
19 All these conditions show the effect of respective compounds in addition to Triton X-
20 100, a constituent of lysis buffer base. The effect of only Triton X-100 (1 % v/v) was
21 checked by addition of lysis buffer base to the sixth tube containing lysate. Values in
22 bracket indicate final concentration of respective compounds in the 50 mL lysate. The

1 tubes containing lysate were incubated on ice for 30 minutes and then spun at 4629 xg
2 to remove cell debris as pellet. The supernatant was further spun at 159,000 xg at 4 °C
3 for 30 minutes. Supernatants obtained after centrifugation at 159,000 xg were
4 transferred to fresh tubes and each pellet was re-suspended in 2 mL T₁₀E₁₀ buffer [10
5 mM Tris (pH 7.6), 10 mM EDTA (ethylenediaminetetraacetic acid)]. 10 µL sample from
6 each condition at all the stages was mixed with 10 µL SDS-PAGE loading dye (2X),
7 heated at 99 °C for 10 minutes and visualized on SDS-PAGE gel. 7 µL was loaded on
8 the gel for total lysate and 159,000 xg pellet while 15 µL was loaded for 4,629 xg
9 supernatant and 159,000 xg supernatant.

10 **Purification of fibril expressed in *E. coli* by Ni-NTA affinity chromatography**

11 A 200 mL culture pellet of *E. coli* BL21 (AI) cells expressing fibril with a terminal His₆ tag
12 (either N-terminal or C-terminal end) was re-suspended in 50 mL lysis buffer [50 mM
13 Tris (pH 7.6), 200 mM NaCl and glycerol 10 % (v/v)]. Cells were lysed using a probe
14 sonicator while incubation on ice and lysate spun at 4629 xg at 4 °C for 15 minutes to
15 remove cell debris as pellet. Supernatant was further spun at 159,000 xg at 4 °C for 30
16 minutes to pellet down fibril filaments. The pellet was re-suspended using 1.8 mL buffer
17 A₂₀₀ [50 mM Tris (pH 7.6), 200 mM NaCl] at room temperature. 200 µL of 10 % (w/v)
18 SDS solution was added and mixed with the re-suspended pellet. The protein
19 suspension was spun at 21,000 xg at 25 °C for 10 minutes to remove any large
20 insoluble aggregates. The soluble fraction from this step was spun at 159,000 xg at 25
21 °C for 30 minutes and fibril was obtained in the supernatant. All the steps after addition
22 of SDS were performed at room temperature (~ 25 °C) since SDS precipitates in cold
23 condition (4 °C).

1 The supernatant was mixed with 2 mL Ni-NTA resin (Ni-NTA agarose; Qiagen) pre-
2 equilibrated with buffer A₂₀₀ (50 mM Tris pH 7.6, 200 mM NaCl) and left for mixing upon
3 gentle agitation at room temperature for 30 minutes. The mixture was put into an empty
4 column with filter. The bound protein was eluted using elution buffer containing
5 increasing concentrations (25 mM, 50 mM, 100 mM, 250 mM and 500 mM) of imidazole
6 in binding buffer. Fractions containing protein of interest were identified on a 12 % SDS-
7 PAGE gel, pooled and concentrated using concentrators. The salts and imidazole were
8 removed by performing 4 cycles of 10-fold dilution of the concentrated protein with
9 sterile distilled water, followed by concentration. The salt-free, concentrated protein was
10 used for visualization using Field Emission-Scanning Electron Microscope (FE-SEM) or
11 Transmission Electron Microscope (TEM).

12 **Purification of insoluble fibril using density gradient**

13 **Preparation of urografin density gradient:** Sterile urografin solution (76 % w/v; Cadila
14 healthcare Ltd, Kundaim, India) was obtained for preparation of density gradients. To
15 prepare a 30.4 % (w/v) solution of urografin, 125 μ L Tris (2 M; pH 7.6) and 500 μ L
16 EDTA (500 mM) were added to 10 mL of urografin in a tube and volume made to 25 mL
17 by addition of distilled water. A 53.2 % (w/v) urografin solution was prepared in a
18 separate tube by addition of 125 μ L Tris (2 M; pH 7.6) and 500 μ L EDTA (500 mM) to
19 17.5 mL of urografin and volume made to 25 mL by addition of distilled water. Both the
20 solutions were vortexed to ensure uniform solution in each tube. The density gradient
21 was prepared by layering 4.5 mL of 30.4 % urografin solution on top of 4.5 mL of 53.2 %
22 urografin solution in an ultra-clear centrifuge tube (Beckman Coulter; catalogue number

1 344059). The tubes were left at room temperature (25 °C) for about 20 hours to allow
2 the formation of a linear gradient.

3 **Purification of fibril from *E. coli* by separation on urografin density gradient**

4 A 500 mL culture pellet of *E. coli* BL21 (AI) cells expressing full length untagged *fibril*
5 (UTF) gene was re-suspended in 60 mL of lysis buffer [10 mM Tris pH 7.6, 1 % (v/v)
6 Triton X-100] and lysed using a probe sonicator. The lysate was spun at 4,629 xg at 4
7 °C for 10 minutes and cell debris in the form of pellet was discarded. The supernatant
8 so obtained was further spun at 159,000 xg to separate fibril filaments (pellet) from the
9 non-polymerized proteins (supernatant). The pellet contained enriched fibril protein and
10 was re-suspended in 1 mL T₁₀E₁₀ buffer [10 mM Tris (pH 7.6), 10 mM EDTA] and left for
11 stirring at 4 °C for about 20 hours. The stirring breaks pellet clumps into finer particles
12 which can be separated on the density gradient.

13 1 mL of stirred enriched fibril was loaded on top of 9 mL urografin density gradient. The
14 tubes containing gradient loaded with protein were spun in a swinging bucket rotor at
15 100,000 xg at 25 °C for 2 hours. The two protein layers were collected as separate
16 fractions using a pipette. Urografin was removed from the fractions by two rounds of
17 washes by diluting it with 65 mL distilled water and spinning at 159,000 xg at 25 °C for
18 30 minutes. The pellet obtained after second round of washing was re-suspended in
19 sterile distilled water (500 µL) and used for visualization on 12 % SDS-PAGE gel along
20 with marker proteins to identify fraction containing fibril.

21 **Visualization of fibril filaments**

1 **Sample preparation for visualization of fibril filaments using Field Emission-**
2 **Scanning Electron Microscopy (FE-SEM):** Pieces (5 mm X 5 mm) of silicon wafer
3 disc (Sigma-Aldrich) were thoroughly washed with 100 % ethanol and stored in 70 %
4 ethanol at room temperature until use. For sample preparation, the silicon wafer pieces
5 were air dried at room temperature to allow evaporation of residual ethanol and water
6 mixture. 2-3 μ L of the fibril purified using affinity chromatography was drop casted on
7 dried silicon wafer pieces and allowed to dry in dust-free environment at 37 °C. 15 nm
8 thick gold coating was then done on the silicon wafer pieces with completely dried
9 protein samples, using sputter coater (Quorum Tech) before visualizing the samples
10 under FE-SEM (ZEISS).

11 **Sample preparation for visualization of fibril filaments using Transmission**
12 **Electron Microscopy (TEM):** Carbon-Formvar coated copper grids (300 mesh; Ted-
13 Pella, Inc) were used without or with glow-discharging [two rounds of 15 mA current for
14 25 seconds using plasma cleaner (Quorum technologies) just before use]. Samples
15 were prepared by applying 2-5 μ L of purified protein to grids and allowed to stand at
16 room temperature for at least 30 seconds to facilitate settling down of the filaments.
17 Excess buffer was blotted using Whatman filter paper (Sigma-Aldrich). 2-4 μ L stain (0.5
18 % w/v uranyl acetate) solution was applied to the grid and immediately absorbed from
19 bottom using blotting paper so as to prevent absorption of the stain by protein. The grids
20 were allowed to dry at room temperature in a dust-free environment for at least 2 hours.
21 Dried grids were stored in a grid storage box in a dry, dust-free environment until
22 observation in a TEM. Grids were scanned using transmission electron microscope

1 (JEM-2200FS, Jeol Ltd.) initially at low magnification and protein imaged at higher
2 magnifications.

3 **Fourier-transform infrared (FT-IR) spectroscopy**

4 His₆-tagged fibril purified using SDS and affinity chromatography followed by dialysis
5 was flash frozen in liquid nitrogen and lyophilized under vacuum for about 48 hours.
6 Similarly, untagged fibril purified by urografin density gradient was also lyophilized to
7 remove traces of water. The dried protein samples were used for collecting FT-IR
8 spectra. Sample transmittance was recorded in the IR spectra (1600-1690 cm⁻¹) with a
9 resolution of 2 cm⁻¹ and 24 scans at each point were acquired in FT-IR
10 Spectrophotometer (NICOLET 6700) using KBr pellet. The transmittance of a sample
11 was normalized by considering its transmittance at 1600 cm⁻¹ as 100 % and the
12 transmittance at other wavelengths as the percentage of transmittance at 1600 cm⁻¹.
13 Values obtained after normalization were subtracted from 1 to obtain absorbance (as
14 percentage) and it is plotted against wave number (cm⁻¹) to identify peaks
15 corresponding to secondary structures.

16 **In-gel trypsin digestion and mass spectroscopy of the protein**

17 Purified/enriched protein was visualized on 12 % SDS-PAGE gels by Coomassie
18 staining. The most prominent bands (corresponding to masses ~ 60,000 Da, ~ 36,000
19 Da and ~ 26,000 Da) were excised from the gel, cut into small pieces and transferred to
20 fresh tubes. Gel pieces were de-stained by re-suspending in buffer containing 40 %
21 acetonitrile and 50 mM TEABC [triethylammonium bicarbonate] for 30 minutes. Stain
22 was removed by spinning the sample (21000 xg at 25 °C for 5 minutes) and discarding

1 the supernatant. The de-staining procedure was repeated 5 times to ensure complete
2 removal of Coomassie stain. Protein in gel was reduced by addition of freshly prepared
3 10 mM DTT (dithiothreitol) to cover gel pieces and incubation at 60 °C for 30 minutes.
4 Excess DTT was then removed and alkylation carried out by addition of 20 mM
5 iodoacetamide and incubation in dark for 15 minutes. Upon incubation iodoacetamide
6 was removed and gel pieces were dehydrated by 4 cycles of washing using acetonitrile
7 (100 %). At the end of 4th cycle, acetonitrile was completely removed and completely
8 dried gel pieces were obtained. The gel pieces were re-hydrated by re-suspension in
9 sequencing grade trypsin (10 ng/μL in 50 mM TEABC) on ice for 60 minutes. Excess
10 trypsin was removed without centrifugation and then gel pieces were re-suspended in
11 20 mM TEABC buffer overnight at 37 °C. Next, trypsin-digested peptides were obtained
12 by spinning the samples (21000 xg at 25 °C for 5 minutes) and collection of
13 supernatant. Remnants of the peptides were extracted from the gel pieces by re-
14 suspending them in varying concentrations of acetonitrile: formic acid (3 % : 0.4 %, 40
15 % : 0.4 % and 100 % acetonitrile) followed by incubation for 10 minutes at room
16 temperature, spinning at 10,000 xg for 10 minutes and harvesting the supernatant. The
17 aliquots of liquid containing peptides were pooled and evaporated using CentriVap DNA
18 vacuum concentrator until dry. The desalting and cleaning of tryptic peptides was
19 performed using StageTip protocol ¹⁹.

20 For LC-MS/MS analysis, a Sciex TripleTOF6600 mass spectrometer interfaced with an
21 Eksigent nano-LC 425 instrument was used. Trypsin-digested peptides (~1 μg) were
22 loaded onto an Eksigent C18 trap column (5 μg capacity) followed by elution on an
23 Eksigent C18 analytical column [15 cm × 75 μm (internal diameter)] using a linear

1 gradient of acetonitrile. A typical liquid chromatography (LC) run consisted of post-
2 loading for 60 min onto the trap at a constant flow rate of 300 nL/minute with solvent A
3 (water and 0.1% formic acid) and solvent B (acetonitrile). The gradient schedule for the
4 LC run was 5 % to 10 % (v/v) B for 2 min, a linear gradient of B from 10 % to 30 % (v/v)
5 over 50 min, 30 % to 90 % (v/v) over 4 min, 90 % (v/v) B for 5 minutes and equilibration
6 with 5 % (v/v) B for 2 minutes. For all the samples data was acquired in information-
7 dependent acquisition (IDA) mode over a mass range of m/z 300 – 1600. Each full MS
8 survey scan was followed by MS/MS of the 13 most intense peptides. Dynamic
9 exclusion was enabled for all experiments (repeat count 2; exclusion duration 5 s).

10 The peptides were identified out using Protein Pilot (version 2.0.1, Sciex) using Pro-
11 Group and Paragon algorithms against the RefSeq protein database of *E. coli* (last
12 downloaded 2021-03-01) with manual addition of fibril sequence (*S. citri*; NCBI RefSeq
13 id WP_071937222.1) without a tag or with a C-terminal 6xHis tag separated by amino
14 acids GS (GSHHHHHH). Iodoacetamide alkylation of cysteine as a static modification
15 and the oxidation of methionine and N-terminal acetylation as variable modifications
16 were defined while searching the peptides. The peptides detected from 2 different
17 batches of each sample were pooled and non-redundant peptides marked on the fibril
18 sequence.

19 **Results**

20 **Fibril filaments withstand treatment with 1 % SDS**

21 Having overexpressed fibril constructs in *E. coli*, we checked the fibril solubility. Fibril
22 filaments were found in the pellet fraction upon 159,000 xg spin of the cell lysate. Re-

1 suspension of fibril from the 159,000 xg pellet in lysis buffer did not give a clear solution,
2 indicating that these filaments were insoluble. Thus, to obtain fibril in soluble form for its
3 further purification, re-suspension and solubilization was attempted using different
4 detergents (Tween 20, LSS, sodium deoxycholate, SDS, Triton X-100) and EDTA.
5 EDTA was selected to depolymerize any nucleotide-dependent filament forming
6 proteins such as MreB, if relevant, and prevent them from pelleting down along with
7 fibril when spun at 159,000 xg. Only the addition of SDS at a final concentration of 1 %
8 (w/v) was found to help in obtaining fibril in the solution (Figure 1B-D).

9 **Fibril purified by SDS treatment followed by Ni-NTA affinity chromatography form** 10 **filament bundles**

11 The small amount of fibril in the lysate (without addition of SDS) did not bind to the Ni-
12 NTA matrix, probably because of occlusion of the filament bundles from the matrix or
13 non-exposure of the hexa-histidine tag. However, the SDS-solubilized (His)₆-fibril bound
14 to Ni-NTA affinity matrix and could be further purified by affinity chromatography (Figure
15 2A). Despite the purification step, additional bands of molecular weight of about 26 kDa
16 were consistently observed along with fibril protein band (at ~ 59 kDa). Fibril protein
17 thus obtained could be dialysed into water, without loss of protein through precipitation.
18 This enabled visualization of the protein using FE-SEM. Visualization of purified fibril
19 using FE-SEM revealed protein bundles or twisted ribbons (Figure 2B). Observation of
20 fibril assemblies using transmission electron microscopy (TEM) revealed that these
21 bundles (Figure 2C and D) are indeed protein filaments assemblies and appeared
22 similar to those reported from *Spiroplasma* ⁵. It is interesting to note that fibril polymers
23 remained unaffected despite treatment with SDS. In order to avoid use of SDS and also

1 to ensure that filament formation was not affected by SDS treatment, an alternative
2 protocol was standardized for purification of fibril, by use of density gradient
3 ultracentrifugation.

4 **Fibril filaments purified using density gradient ultracentrifugation are present as** 5 **bundles**

6 Resuspended fibril pellet obtained after 159,000 xg ultracentrifugation separated into 2
7 different bands on the urografin density gradient (Figure 3A). Visualization of the protein
8 in the two bands on SDS-PAGE gel after removal of urografin by dilution and pelleting
9 revealed that the lower band contains enriched fibril (Figure 3A, lane 6). Electron
10 microscopy observation of the samples revealed filament bundles similar to that
11 obtained with SDS treatment (Figure 3B-D).

12 Next we investigated if the SDS treatment affected fibril by comparing secondary
13 structures of fibril purified with and without the use of SDS using FT-IR spectroscopy.

14 **Fibril filaments exhibit secondary structure content of α -helices and β -sheets**

15 The FT-IR spectra for fibril purified with or without SDS (using urografin density
16 gradient) shows similar profiles (Fig 4). All the three protein constructs show the
17 presence of peaks corresponding to α -helices (1655 cm^{-1}), β -turns (1685 cm^{-1}) and β -
18 sheets (1636 cm^{-1})^{20,21} suggesting the presence of these secondary structures in the
19 fibril constructs purified by different protocols. Thus, based on FT-IR data we conclude
20 that fibril is not an amyloid-like aggregate of protein, but has specific secondary
21 structures, alpha helices and beta sheet.

1 Having confirmed the stability of fibril upon SDS treatment, we decided to explore the
2 identity of low molecular weight proteins accompanying fibril, a 59 kDa protein. The
3 most prominent of these proteins were bands corresponding to molecular weight of ~ 36
4 kDa and ~ 26 kDa (Figure 3A, lanes 5, 6). These bands appear to be similar to those
5 observed during purification of His₆-tagged fibril using SDS and affinity chromatography
6 (Figure 2A) as well as in the supernatant and pellet fractions at stages of differential
7 centrifugation steps (Figure 2A and 3A). This led us to hypothesize that the ~ 36 kDa
8 and 26 kDa proteins must be either breakdown products of fibril or are contaminant
9 proteins with the molecular weight of about ~ 26 kDa having affinity to the Ni-NTA matrix
10 or fibril. Thus we performed mass spectrometry study to reveal the identity of these
11 proteins.

12 **Proteolytic fragments of fibril identify approximate domain boundaries of fibril**

13 Analysis of the peptides obtained from the ~ 36 kDa and ~ 26 kDa proteins
14 accompanying enriched fibril purified by density gradient and ~ 26 kDa proteins
15 associated with purified His-tagged fibril by in-gel trypsin digestion revealed that these
16 are indeed breakdown products of full-length fibril (Figure 5). This suggests that fibril got
17 proteolysed during heterologous expression in *E. coli* or the purification procedure.
18 However, the fragments were retained with the fibril polymers most likely because they
19 form an integral core of the fibril filament, and proteolysis occurred at the exposed loops
20 in the polymerized state.

21 Analysis of fibril protein sequence revealed that its proteolysis around residues L²²⁰ or
22 G³¹² can result into complementary fragments with molecular weights of ~ 36 kDa and

1 26 kDa. These suggest that the peptides consisting 1-220 could constitute the amino-
2 terminal domain while residues 312-512 make up the carboxy-terminal domain (Figure
3 5). The region consisting of residues 220-312 could potentially be the flexible linker
4 connecting the two domains with each other.

5 **Discussion and Conclusions**

6 The ability to control protein polymerization often proves useful for its purification ²².
7 Thus actin, tubulin and their bacterial homologs were the initial cytoskeletal proteins to
8 be purified and hence are well characterized. In contrast, intermediate filaments and
9 other classes of constitutive filaments such as pili, flagella form stable, insoluble
10 polymers and hence require treatment with denaturing agents like guanidine
11 hydrochloride or urea for solubilizing them to enable their purification ²³. Similarly,
12 constitutive filament-forming proteins from bacteria, bactofilins and crescentin, were
13 purified using denaturing condition (6 M urea or 6 M guanidium chloride) or using
14 gradient centrifugation ²⁴⁻²⁶. Use of proteins purified by denaturation-purification-
15 renaturation protocols for structural studies is tricky because of the risk of not knowing
16 the correct folded state. These challenges associated with purification of constitutive
17 filaments forming proteins have limited our understanding about their structure and
18 function. Fibril is one such nucleotide-independent polymerizing protein classified as a
19 cytoskeletal element ^{2,27}. The role of conformational changes in fibril was hypothesized
20 long ago ⁸ but different conformations of fibril have not yet been observed at molecular
21 level.

1 During the initial attempts of purification we found that fibril remains insoluble upon
2 pelleting at forces higher than 100,000 xg. The detergent screen revealed that fibril
3 could not be solubilized by Tween-20, N-lauroyl sarcosine sodium salt, Triton X-100 or
4 sodium deoxycholate but only using SDS (1 % W/V). Similar resistance of fibril has
5 earlier been observed for 8 M urea ²⁸. In addition to solubilization of fibril, the SDS
6 treatment also exposed its 6xHis-tag thereby facilitating its purification by affinity
7 chromatography. Since use of SDS, an anionic detergent, can denature proteins ²⁹, we
8 visualized the SDS-treated fibril to check if the protein was aggregated rather than
9 forming filaments. To our surprise, we found that fibril was present as polymers. The
10 observation of characteristic twists in the fibril ribbon was observed using FE-SEM. The
11 assemblies of SDS-treated fibril are similar to those isolated from *Spiroplasma* ⁵ and
12 suggest that fibril is resistant to SDS treatment. In order to develop a SDS-free fibril
13 purification protocol, we used urografin density gradient to enrich insoluble fibril.
14 Visualization of fibril purified using density gradient by TEM revealed morphologically
15 similar assemblies to those purified using SDS as well as reported in literature ⁵.

16 The fibril purified by density gradient centrifugation was accompanied by low molecular
17 weight proteins (~ 26 kDa and ~ 36 kDa). Also, the 6xHis tagged fibril (irrespective of
18 the presence of tag at the N or C terminus), the ~ 26 kDa bands remain associated with
19 full-length fibril (59 kDa) even after purification by affinity chromatography. Mass
20 spectroscopy analysis of these proteins accompanying fibril suggested these to be the
21 break down products of fibril. Thus, the residues constituting ~ 26 kDa (about 240 amino
22 acids) from each end must constitute the two domains of fibril. Approximately 30
23 residues between the N and C-terminal domains must be forming a linker. This

1 information is useful to design short constructs of fibril to identify its soluble domains,
2 perform structural characterization and study their polymerization properties. Fibril
3 purified with or without use of SDS showed similar FT-IR profiles re-assuring that SDS
4 treatment did not denature fibril. The FT-IR profiles also revealed that fibril is not ‘only α -
5 helical’ or ‘only cross- β sheets’ structure formed by α -keratin and amyloid fibrils
6 respectively^{30,31}, but forms both α helices and well as β sheets constituting a globular
7 protein domain.

8 In absence of structural information on fibril, we added the 6xHis tag at the amino or
9 carboxy terminus of fibril to attempt its purification by affinity chromatography without
10 affecting its polymerization. However, we observed that the fibril did not bind the Ni-NTA
11 affinity matrix without SDS treatment. This suggested to us that the terminal 6xHis tag
12 was not exposed and may be buried during protein folding or at the polymerization
13 interface. The challenge of deciding the site of insertion of a tag such that the function is
14 not affected holds true for proteins of unknown fold and is further complicated for the
15 proteins that assemble into polymers/oligomers, as was the case of fibril. This limits the
16 options to purify proteins of interest in high quantities, with maximum purity for
17 biochemical and structural characterization, similar to those obtained by
18 chromatography techniques. In such cases, density gradient centrifugation (DGC) is
19 useful for purifying the protein of interest based on its density. The technique is widely
20 used for the separation of macromolecular assemblies such as protein polymers,
21 viruses and lipoproteins from other biomolecules³²⁻³⁵. The DGC remains as the
22 technique of choice for label-free purification of biomolecules, especially filament
23 assemblies³⁶⁻³⁸.

1 In summary, we have performed characterization of fibril and standardized protocols for
2 its purification. Our approach helps obtain purified protein in quantities sufficient for
3 structural studies and biochemical characterization of fibril using *E. coli*. Another use of
4 the standardized heterologous expression system for fibril is its domain dissection. The
5 lack of sophisticated tools for genetic modification of *Spiroplasma* has hindered the
6 progress of structural characterization of full-length fibril and identification of domains by
7 genetic screens. The genetically refractive nature of *Spiroplasma* has even prevented
8 researchers from dissecting fibril to identify its domain boundaries and polymerization
9 interface. In such a situation use a genetically facile organism becomes obligatory. Our
10 demonstration of obtaining purified, folded fibril using *E. coli* paves way for expression
11 and purification of short constructs of fibril to confirm its domain boundaries and
12 polymerization interfaces. The system also opens up avenues for testing interaction of
13 fibril and other *Spiroplasma* proteins such as MreB¹⁰, *in vivo* using *E. coli* by co-
14 localization studies using fluorescent tags.

15 **Acknowledgements**

16 This work is supported by funds from Department of Science and technology (DST)
17 INSPIRE Faculty Fellowship (IFA12/LSBM-52), Innovative Young Biotechnologist
18 Award (BT/07/IYBA/2013), Department of Biotechnology Membrane Structural Biology
19 Programme Grant (BT/PR28833/BRB/10/1705/2018) and funds from IISER Pune to P.
20 Gayathri. SH acknowledges IISER Pune and Infosys foundation (IISER-P/InfyFnd/Trv/1)
21 for the fellowship. Electron microscopy facility at IISER Pune (supported by DST-
22 Nanomission (EMR/2016/003553), proteomics facility funded by Department of Science
23 and Technology Fund for Improvement of S&T Infrastructure (DST-FIST; SR/FST/LSII-

1 043/2016) to IISER Pune Biology department and associated staff at IISER Pune is
2 acknowledged. Preliminary electron microscopy experiments were carried out at the
3 electron microscopy facility at the Indian Institute of Science Bangalore. Mr. Anil
4 Prathamshetty, Physics department, IISER Pune, is acknowledged for technical help
5 with FE-SEM experiments. Authors also acknowledge Prof. Jayant Udgaonkar for the
6 access to mass spectroscopy facility, Dr. Harish Kumar and Mr. Kundan Kumar of
7 IISER Pune for their technical help for mass spectrometry sample preparation and
8 analysis.

9 **References**

- 10 1. Townsend R, Archer DB (1983) A Fibril protein antigen specific to *Spiroplasma*. J.
11 Gen. Microbiol. 129:199–206.
- 12 2. Townsend R, Archer DB, Plaskitt KA (1980) Purification and preliminary
13 characterization of *Spiroplasma* fibrils. J. Bacteriol. 142:694–700.
- 14 3. Trachtenberg S, Gilad R (2001) A bacterial linear motor: Cellular and molecular
15 organization of the contractile cytoskeleton of the helical bacterium *Spiroplasma*
16 *melliferum* BC3. Mol. Microbiol. 41:827–848.
- 17 4. Cohen-Krausz S, Cabahug PC, Trachtenberg S (2011) The monomeric, tetrameric,
18 and fibrillar organization of Fib: the dynamic building block of the bacterial linear motor
19 of *Spiroplasma melliferum* BC3. J. Mol. Biol. 410:194–213.
- 20 5. Sasajima Y, Kato T, Miyata T, Namba K, Miyata M (2021) Elucidation of fibril
21 structure responsible for swimming in *Spiroplasma* using electron microscopy. bioRxiv.

- 1 6. Kürner J, Frangakis AS, Baumeister W (2005) Cryo – electron tomography reveals
2 the cytoskeletal structure of *Spiroplasma melliferum*. *Science* 307:436–439.
- 3 7. Trachtenberg S, Dorward LM, Speransky V V., Jaffe H, Andrews SB, Leapman RD
4 (2008) Structure of the cytoskeleton of *Spiroplasma melliferum* BC3 and its interactions
5 with the cell membrane. *J. Mol. Biol.* 378:778–789.
- 6 8. Razin S (1978) The Mycoplasmas. *Microbiol Rev* 42:414—470.
- 7 9. Shaevitz JW, Lee JY, Fletcher DA (2005) *Spiroplasma* swim by a processive change
8 in body helicity. *Cell* 122:941–945.
- 9 10. Harne S, Duret S, Pande V, Bapat M, Béven L, Gayathri P (2020) MreB5 is a
10 determinant of rod-to-helical transition in the cell-wall-less bacterium *Spiroplasma*. *Curr.*
11 *Biol.* 30:4753–4762.
- 12 11. Liu P, Zheng H, Meng Q, Terahara N, Gu W, Wang S, Zhao G, Nakane D, Wang W,
13 Miyata M (2017) Chemotaxis without conventional two-component system, based on
14 cell polarity and aerobic conditions in helicity-switching swimming of *Spiroplasma*
15 *eriocheiris*. *Front. Microbiol.* 8:1–13.
- 16 12. Williamson DL, Renaudin J, Bové JM (1991) Nucleotide sequence of the
17 *Spiroplasma citri* fibril protein gene. *J. Bacteriol.* 173:4353–4362.
- 18 13. Bové JM, Carle P, Garnier M, Laigret F, Renaudin J, Saillard C Molecular and
19 cellular biology of spiroplasmas. In: Whitcomb RF, Tully JG, editors. *The Mycoplasmas*.
20 Vol. V. ; 1989. pp. 243–364.
- 21 14. Pande V, Mitra N, Bagde SR, Srinivasan R, Gayathri P (2021) Filament dynamics

- 1 driven by ATP hydrolysis modulates membrane binding of the bacterial actin MreB.
2 bioRxiv:1–41.
- 3 15. Takahashi D, Fujiwara I, Sasajima Y, Narita A, Imada K, Miyata M (2021) Structure
4 and polymerization dynamics of bacterial actin MreB3 and MreB5 involved in
5 *Spiroplasma* swimming. bioRxiv.
- 6 16. Harne S, Gayathri P, Béven L (2020) Exploring *Spiroplasma* biology: opportunities
7 and challenges. Front. Microbiol. 11:1–8.
- 8 17. Merino F, Pospich S, Funk J, Wagner T, Küllmer F, Arndt HD, Bieling P, Raunser S
9 (2018) Structural transitions of F-actin upon ATP hydrolysis at near-atomic resolution
10 revealed by cryo-EM. Nat. Struct. Mol. Biol. 25:528–537.
- 11 18. Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther
12 RA, Ghetti B, Goedert M, Scheres SHW (2017) Cryo-EM structures of tau filaments
13 from Alzheimer’s disease. Nature 547:185–190.
- 14 19. Rappsilber J, Mann M, Ishihama Y (2007) Protocol for micro-purification,
15 enrichment, pre-fractionation and storage of peptides for proteomics using StageTips.
16 Nat. Protoc. 2:1896–1906.
- 17 20. Kim Y, Rose CA, Liu Y, Ozaki Y, Datta G, Tu AT (1994) FT-IR and near-infrared FT-
18 Raman studies of the secondary structure of insulinotropin in the solid state: α -helix to
19 β -sheet conversion induced by phenol and/or by high shear force. J. Pharm. Sci.
20 83:1175–1180.
- 21 21. Adochitei A, Drochioiu G (2011) Rapid characterization of peptide secondary

- 1 structure by FT-IR spectroscopy. Rev. Roum. Chim. 56:783–791.
- 2 22. van den Ent F, Møller-Jensen J, Amos L a., Gerdes K, Löwe J (2002) F-actin-like
- 3 filaments formed by plasmid segregation protein ParM. EMBO J. 21:6935–6943.
- 4 23. Herrmann H, Aebi U (2016) Intermediate filaments: Structure and assembly. Cold
- 5 Spring Harb. Perspect. Biol. 8:1–22.
- 6 24. Koch MK, McHugh CA, Hoiczuk E (2011) BacM, an N-terminally processed
- 7 bactofilin of *Myxococcus xanthus*, is crucial for proper cell shape. Mol. Microbiol.
- 8 80:1031–1051.
- 9 25. Deng X, Llamazares AG, Wagstaff JM, Hale VL, Cannone G, McLaughlin SH,
- 10 Kureisaite-Ciziene D, Löwe J (2019) The structure of bactofilin filaments reveals their
- 11 mode of membrane binding and lack of polarity. Nat. Microbiol. 4:2357–2368.
- 12 26. Esue O, Rupprecht L, Sun SX, Wirtz D (2010) Dynamics of the bacterial
- 13 intermediate filament crescentin *in vitro* and *in vivo*. PLoS One 5:e8855.
- 14 27. Williamson DL (1974) Unusual fibrils from the spirochete-like sex ratio organism. J.
- 15 Bacteriol. 117:904–6.
- 16 28. Townsend R (1983) *Spiroplasma* fibrils. Yale J. Biol. Med. 56:447–52.
- 17 29. Giancola C, De Sena C, Fessas D, Graziano G, Barone G (1997) DSC studies on
- 18 bovine serum albumin denaturation effects of ionic strength and SDS concentration. Int.
- 19 J. Biol. Macromol. 20:193–204.
- 20 30. Pouling L, Corey RB, Branson HR (1951) The structure of proteins: two hydrogen-

- 1 bonded helical configurations of the polypeptide chain. Proc. Natl. Acad. Sci. USA
- 2 37:205–211.
- 3 31. Eanes ED, Glenner GG (1968) X-ray diffraction studies on amyloid filaments. J.
- 4 Histochem. Cytochem. 16:673–677.
- 5 32. Chung BH, Wilkinson T, Geer JC, Segrest JP (1980) Preparative and quantitative
- 6 isolation of plasma lipoproteins: rapid , single discontinuous density gradient
- 7 ultracentrifugation in a vertical rotor. J. Lipid Res. 21:284–291.
- 8 33. Redgrave TG, Roberts DCK, West CE (1975) Separation of plasma lipoproteins by
- 9 density-gradient untracentrifugation. Anal. Biochem. 65:42–49.
- 10 34. Reimer CB, Baker RS, VanFrank RM, Newlin TE, Cline GB, Anderson NG (1967)
- 11 Purification of large quantities of influenza virus by density gradient centrifugation. J.
- 12 Virol. 1:1207–1216.
- 13 35. Soellner P, Quinlan RA, Franke WW (1985) Identification of a distinct soluble
- 14 subunit of an intermediate filament protein: tetrameric vimentin from living cells. Proc.
- 15 Natl. Acad. Sci. U. S. A. 82:7929–7933.
- 16 36. Mamada N, Tanokashira D, Ishii K, Tamaoka A, Araki W (2017) Mitochondria are
- 17 devoid of amyloid β -protein ($A\beta$)-producing secretases: evidence for unlikely occurrence
- 18 within mitochondria of $A\beta$ generation from amyloid precursor protein. Biochem. Biophys.
- 19 Res. Commun. 486:321–328.
- 20 37. Yin C, Goonawardane N, Stewart H, Harris M A role for domain I of the hepatitis C
- 21 virus NS5A protein in virus assembly. 2018.

1 38. Samuel M, Chisanga D, Liem M, Keerthikumar S, Anand S, Ang CS, Adda CG,
2 Versteegen E, Jois M, Mathivanan S (2017) Bovine milk-derived exosomes from
3 colostrum are enriched with proteins implicated in immune response and growth. *Sci.*
4 *Rep.* 7:1–10.

5 **Figure legends**

6 **Figure 1. Cytoskeletal organization of *Spiroplasma* fibril and its heterologous** 7 **expression and solubility check**

8 A) Pictorial representation of intra-cellular localization of cytoskeletal ribbon of
9 *Spiroplasma* (i) is shown. Longitudinal section (represented within the black box in (i)) of
10 *Spiroplasma* cell showing schematic representation of fibril and MreB organization as
11 proposed by Kürner et al., 2005 (ii) and Trachtenberg et al., 2008 (iii). According to
12 Kürner et al., (2005), fibril filaments flank the MreB filaments while Trachtenberg et al.,
13 (2008) proposes that the MreB filaments are sandwiched between fibrils and
14 membrane. B - D) Solubility check of fibril overexpressed in *E. coli* using different
15 detergents [sodium dodecyl sulphate (SDS), sodium deoxycholate (Sod deoxycholate),
16 N-lauroylsarcosine sodium salt (LSS)] and ethylenediaminetetraacetic acid (EDTA).
17 Lanes correspond to total lysate (1), supernatant after spinning the lysate at 4,629 xg
18 (2), supernatant (3) and pellet (4) after 159,000 xg spin of the clarified lysate. Addition of
19 SDS (1 % w/v) helped obtain fibril soluble upon 159,000 xg centrifugation and is
20 highlighted with a red box.

21

1 **Figure 2. Purification of hexahistidine-tagged fibril by SDS treatment and affinity**
2 **chromatography.** A) A 12 % SDS-PAGE gel showing purity of fibril at different stages of
3 purification. Lanes correspond to total lysate (1), supernatant after spinning clarified
4 lysate at 4,629 xg (2), supernatant (3) and pellet (4) after 159,000 xg spin of the clarified
5 lysate, supernatant of the 159,000 xg pellet solubilized using 1 % SDS (w/v) followed by
6 spin at 21,000 xg (5), supernatant obtained after spinning the soluble protein from step
7 5 at 159,000 xg (6), protein fraction purified using Ni-NTA affinity chromatography (7).
8 Scanning electron microscopy (SEM; B) and negative staining transmission electron
9 microscopy (TEM; C and D) images of fibril filaments purified using SDS treatment
10 followed by affinity chromatography.

11
12 **Figure 3. Purification of untagged fibril using urografin density gradient.** A) A 12 %
13 SDS-PAGE gel showing purity of fibril at different stages of purification. Lanes
14 correspond to protein marker (M), total lysate (1), supernatant after spinning lysate at
15 8,000 xg (2), supernatant (3) and pellet (4) after spinning 8,000 xg supernatant at
16 159,000 xg respectively, top (5) and bottom (6) layers formed on the gradient by
17 separation of 159,000 xg pellet fraction. Upon purification, the protein migration is
18 retarded due to residual urografin associated with the protein. B-D) Negative staining
19 transmission electron microscopy (TEM) images of fibril filaments purified using
20 urografin density gradient. Individual thin filaments are visible in the images.

21
22 **Figure 4. Fibril remains unaffected by SDS treatment.** FT-IR analysis of untagged
23 fibril (UTF) purified using urografin density gradient, His₆-fibril (N-terminal His₆ fibril;





1 NHFF) and fibril-His₆ (C-terminal His₆ fibril; CHFF) purified by SDS treatment followed
2 by affinity chromatography shows similar peak pattern. All the three protein constructs
3 display peaks around 1655, 1636 and 1685 cm⁻¹ corresponding to α -helices, β -sheets
4 and β -turn secondary structures, respectively. This data indicates that fibril is not
5 affected by the SDS treatment employed for its purification.

6
7 **Figure 5. Fibril is proteolyzed in the cell.** Mass spectrometry analysis of trypsin-
8 digested peptides of about 59,000 Da, 36,000 Da and 26,000 Da bands observed
9 during the purification of untagged fibril (UTF) and fibril with a C-terminal 6xHis tag
10 (CHFF) by mass spectrometry study revealed that the 36,000 Da and 26,000 Da bands
11 are indeed breakdown products of fibril. Amino acid sequences of individual peptides
12 detected by mass spectrometer are represented by lines below the corresponding
13 sequence while secondary structures (grey arrows- strands, grey sheets- helices) as
14 predicted using PSIPRED (<http://bioinf.cs.ucl.ac.uk/psipred/>) are shown above the
15 sequence and residue numbers are shown in superscript. Black arrows point to the
16 potentially exposed trypsin protease target sites. Values in brackets next to black arrows
17 indicate the masses in kilodalton (kDa) of the amino and carboxy-terminal fragment if
18 the trypsin cleaved fibril at that position.

1 **Supplementary table 1. List of primers used for amplification and cloning of *fibril***
 2 **gene into pHIS17 vector.**





Primer name	Sequence (5' → 3')	Purpose
ScFib-f	GTTTAACTTTAAGAAGGAGATATACATATGATCGGTGTAATT TCAACAGCATATTTTACG	Amplification and cloning of <i>fibril</i> gene with or without a terminal 6xHis tag
ScFib-r	GCTTTTAATGATGATGATGATGATGGGATCCATCATTACTCA CTTTTAAACGAATTGTAACCTTG	
ScFib-NHis-f	CTTTAAGAAGGAGATATACATATGCGTGGCCATCATCATCAT CATCATCATATCGGTGTAATTTCAAC	
ScFib-CHis-r	GCTTTTAATGATGATGATGATGATGGGATCCATCATTCTCAC TTTTTAAACGAATTGTAACCTTG	
ScF-W25-f	CAGTAAAAAATATGCGTGGAAGAACTGTGTAATTC	Mutation of codons for tryptophan (TGA to TGG).
ScF-W200-f	AATGCATTATCACCATGGGATAATGATCCAATCCATA	
ScF-W200-r	TATGGATTGGATCATTATCCCATGGTGATAATGCATT	
ScF-W258-f	GAAATTAAACATGACCAATGGATTAAATTATTTAAACC	
ScF-W258-r	GGTTTAAATAATTTAATCCATTGGTCATGTTTAATTC	
ScF-W316-322-f	GTAATTTTAGGAGAGGATGAATGGAAAAATGCTCCTAAAAAA TGGTTACGTAAATTATTA	
ScF-W342-r	CATATTTTGCTGATTTATTCCATAATAATTCATCATCAT	
T7-Promoter	TAATACGACTCACTATAGGG	Clone sequencing
T7-Terminator	GCTAGTTATTGCTCAGCGG	

Figure 1



bioRxiv preprint doi: <https://doi.org/10.1101/2021.10.30.466559>; this version posted October 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.


Figure 2




bioRxiv preprint doi: <https://doi.org/10.1101/2021.10.30.466559>; this version posted October 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 3


A



B



C



D





Figure 4



bioRxiv preprint doi: <https://doi.org/10.1101/2021.10.30.466559>; this version posted October 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 5

